SPIRIT-DEFINE explanation and elaboration: recommendations for enhancing quality and impact of early phase dose-finding clinical trials protocols

Archive ouverte

Ursino, Moreno | Villacampa, Guillermo | Rekowski, Jan | Dimairo, Munyaradzi | Solovyeva, Olga | Ashby, Deborah | Berlin, Jordan | Boix, Oliver | Calvert, Melanie | Chan, An-Wen | Coschi, Courtney | Evans, Thomas | Garrett-Mayer, Elizabeth | Golub, Robert | Guo, Christina | Hayward, Kathryn | Hopewell, Sally | Isaacs, John | Ivy, S. Percy | Jaki, Thomas | Kholmanskikh, Olga | Kightley, Andrew | Lee, Shing | Liu, Rong | Mander, Adrian | Marshall, Lynley | Matcham, James | Patel, Dhrusti | Peck, Richard | Rantell, Khadija Rerhou | Richards, Dawn | Rouhifard, Mahtab | Seymour, Lesley | Tanaka, Yoshiya | Weir, Christopher | de Bono, Johann | Yap, Christina

Edité par CCSD ; Elsevier -

International audience. Transparent and accurate reporting in early phase dose-finding (EPDF) clinical trials is crucial for informing subsequent larger trials. The SPIRIT statement, designed for trial protocol content, does not adequately cover the distinctive features of EPDF trials. Recent findings indicate that the protocol contents in past EPDF trials frequently lacked completeness and clarity. To address this gap, the international consensus-driven SPIRIT-DEFINE checklist was developed through a robust methodological framework for guideline development, with the aim to improve completeness and clarity in EPDF trial protocols. The checklist builds on the SPIRIT statement, adding 17 new items and modifying 15 existing ones.The SPIRIT-DEFINE explanation and elaboration (E&E) document provides comprehensive information to enhance understanding and usability of the SPIRIT-DEFINE checklist when writing an EPDF trial protocol. Each new or modified checklist item is accompanied by a detailed description, its rationale with supportive evidence, and examples of good reporting curated from EPDF trial protocols covering a range of therapeutic areas and interventions. We recommend utilising this paper alongside the SPIRIT statement, and any relevant extensions, to enhance the development and review of EPDF trial protocols.By facilitating adoption of the SPIRIT-DEFINE statement for EPDF trials, this E&E document can promote enhancement of methodological rigour, patient safety, transparency, and facilitate the generation of high-quality, reproducible evidence that will strengthen the foundation of early phase research and ultimately improve patient outcomes.

Consulter en ligne

Suggestions

Du même auteur

CONSORT-DEFINE explanation and elaboration: recommendations for enhancing reporting quality and impact of early phase dose-finding clinical trials

Archive ouverte | Rekowski, Jan | CCSD

International audience. Early phase dose-finding (EPDF) trials are key in the development of novel therapies, with their findings directly informing subsequent clinical development phases and providing valuable insi...

Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance

Archive ouverte | Yap, Christina | CCSD

International audience. The CONSORT (CONsolidated Standards Of Reporting Trials) 2010 statement is the standard guideline for reporting completed randomised trials. The CONSORT Dose-finding Extension (DEFINE) extend...

Enhancing quality and impact of early phase dose-finding clinical trial protocols: SPIRIT Dose-finding Extension (SPIRIT-DEFINE) guidance

Archive ouverte | Yap, Christina | CCSD

International audience

Chargement des enrichissements...